ACADIA Pharmaceuticals Inc. (ACAD)

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the U.S. Food and Drug Administration (FDA) has approved DAYBUE® STIX (trofinetide) for oral solution, a dye...

Acadia (ACAD) reported earnings 30 days ago. What's next for the stock?...

Fisher Asset Management LLC decreased its position in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 12.6% in the second quarter, according to the company in its most recent 13F filing with t...

Acadia Pharmaceuticals Inc. is rated Buy for its steady NUPLAZID/DAYBUE franchises and pipeline-driven upside potential. NUPLAZID's patent protection now extends to 2030, supporting >10% Y/Y revenue g...

Connecticut-based fund Braidwell bought 2,378,655 shares of Acadia Pharmaceuticals in the third quarter, representing a new position valued at about $50.8 million as of September 30. The transaction r...

ACADIA Pharmaceuticals Inc. (ACAD) Presents at Citi Annual Global Healthcare Conference 2025 Transcript...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....

SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that it will participate in a fireside chat at Citi's 2025 Global Healthcare Conference on Tuesday, December 2, 2...

Envestnet Asset Management Inc. increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) by 14.0% during the undefined quarter, according to the company in its most recent Form 13F ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage....